In January–June 2022, Russia manufactured 366 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 28.4% from January–June 2021. In physical terms, the production volume was 2.14 billion packages, up 5.9% from the same period in 2021. If calculated in minimum dosage units (MDU), Russia produced 40.5 billion MDUs, up 3.3% from January–June 2021.

In January–June 2022, Russia imported 106.4 billion rubles’ worth of APIs (customs clearance and VAT included), up 3.7% from January–June 2021, a five-year low. In physical terms, the growth rate was 21%, a twelve-year high, with around 10,000 tons imported, a six-month high.

Only 1.1% expect a salary raise after the changes to payments to healthcare workers dealing with COVID-19 patients are introduced, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. At the same times, about 2.2% of the physicians believe that their salaries might decrease only a little, by no more than 10%. Another 2.9% expect neither an increase nor decrease, saying that “everything will remain more or less the same.”

In Q1–Q2 2022, Russia imported 397.8 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 8.7% from Q1–Q2 2021. As for bulk drugs, the import volume was 94.4 million rubles, up as much as 32.6% from Q1–Q2 2021. In physical terms, however, the growth rates were negative for both groups: –9.4% for ready-made drugs, with 803 million packages imported, and –32.7% for bulk drugs, with 731.4 million MDUs (minimum dosage units) imported.

The Laspeyres price index for APIs imported to Russia in Q1–Q2 2022 was –1%, marking the first time in the past 5 years that the prices for foreign APIs have been declining. Besides, this is only the fifth deflation in the past 12 years, the last time dating back to 2017. After that, in 2018–2020, the Russian market witnessed a galloping inflation. In late 2020, the inflation rate hit a historic high, when the pandemic stopped API production in China and the prices jumped by nearly 24%.

In January–May 2022, Russia imported 15.6 billion rubles’ worth of veterinary drugs (customs clearance and VAT included), 2.6% down from January–May 2021, and 19.3 billion rubles’ worth of feed supplements, up 11.8% from the same period in 2021. Notably, feed supplements for pets helped the growth rates, having increased 2.2 times against January–May 2021. As for veterinary drugs, imports of products for both livestock animals and pets went down.

In January–May 2022, Russia imported 333.1 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 7% from the same period in 2021. As for bulk drugs, the import was 70.4 billion rubles, up 11.6% from January–May 2021. In physical terms, the growth rates were negative for both groups: –10% for ready-made drugs (660 million packages), and –31% for bulk drugs (655.8 million minimum dosage units—MDUs).

In January–May 2022, Russia imported 91 billion rubles’ worth of APIs (customs clearance and VAT included), up 7.4% from January–May 2021. In physical terms, the growth rate was 16.7%, with 8,600 tons imported.

In January–May 2022, Russian manufacturers produced 311.1 billion rubles’ worth of pharmaceutical drugs (manufacturer’s prices, VAT included), more than 30% up from January–May 2021. In physical terms, the production volume was 1.8 billion packages, up 5.6% from January–May 2021. If calculated in minimum dosage units (MDUs), the manufacture was 33.5 billion MDUs (up 2.7%).

From January to May 2022, the offline sales of veterinary drugs in the Russian retail market were 9.1 billion RUB (retail prices, VAT included), down 0.2% from January–May 2021, which means that the market is stagnating, pressured by the online segment. In physical terms, the volume was 56.6 million minimum dosage units (MDU), down 18.4% in MDUs.